{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:02:29Z","timestamp":1791093749451,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Intra-peritoneal (i.p.) chemotherapy is an encouraging treatment option for ovarian cancer with peritoneum involvement in addition with intravenous (i.v.) chemotherapy. Intra-operative i.p. chemotherapy is an interesting method of administration by enhancing the diffusion of chemotherapy. This study had assessed the feasibility of intra-operative i.p. chemotherapy in patients with peritoneal carcinoma of ovarian cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From January 2003 to February 2006, 47 patients with stage III ovarian cancer were treated with standard paclitaxel carboplatin intravenous chemotherapy and debulking surgery with intra-operative i.p. chemotherapy. After optimal cytoreductive surgery, defined by no unresectable residual disease &gt; 1 cm, i.p. chemotherapy was performed during surgery. The peritoneal cavity was filled by 3 litres of isotonic saline pre-heated at 37 degrees and 90 mg of cisplatin. The sequence was repeated twice during 2 hours based on previous published studies which optimized the cisplatin dosage and exposure duration. Optimal diffusion was obtained by stirring by hands during the 2 hours.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Median age was 59.6 years. No severe haematological or non-haematological toxicity induced by intra operative i.p. chemotherapy was reported. No patient died due to the complications of surgery or the i.p. chemotherapy. No neurotoxicity occurred, and one patients had renal impairment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study demonstrates the feasibility of intra-operative i.p. chemotherapy with cisplatin after optimal resection of peritoneal tumor nodules. Further randomized trials are planned to investigate the clinical benefit of this therapeutic modality.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7819-7-14","type":"journal-article","created":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T07:12:09Z","timestamp":1234249929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer"],"prefix":"10.1186","volume":"7","author":[{"given":"Emmanuel","family":"Guardiola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Delroeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Heyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Lorgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Demarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Chauffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pivot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,9]]},"reference":[{"key":"551_CR1","doi-asserted-by":"publisher","first-page":"16S","DOI":"10.1097\/00002820-200312001-00005","volume":"26","author":"LA Almadrones","year":"2003","unstructured":"Almadrones LA: Treatment advances in ovarian cancer. Cancer Nurs. 2003, 26: 16S-20S. 10.1097\/00002820-200312001-00005.","journal-title":"Cancer Nurs"},{"issue":"Suppl 1","key":"551_CR2","first-page":"S22","volume":"8","author":"RF Ozols","year":"2002","unstructured":"Ozols RF: Update on the management of ovarian cancer. Cancer J. 2002, 8 (Suppl 1): S22-30.","journal-title":"Cancer J"},{"key":"551_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1586\/14737140.4.3.477","volume":"4","author":"CP Carmignani","year":"2004","unstructured":"Carmignani CP, Sugarbaker PH: Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience. Expert Rev Anticancer Ther. 2004, 4: 477-487. 10.1586\/14737140.4.3.477.","journal-title":"Expert Rev Anticancer Ther"},{"key":"551_CR4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA: Cancer of the ovary. N Engl J Med. 2004, 351: 2519-2529. 10.1056\/NEJMra041842.","journal-title":"N Engl J Med"},{"key":"551_CR5","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1056\/NEJMe048292","volume":"351","author":"T Thigpen","year":"2004","unstructured":"Thigpen T: The if and when of surgical debulking for ovarian carcinoma. N Engl J Med. 2004, 351: 2544-2546. 10.1056\/NEJMe048292.","journal-title":"N Engl J Med"},{"key":"551_CR6","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0090-8258(03)00472-4","volume":"90","author":"GC Stuart","year":"2003","unstructured":"Stuart GC: First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol. 2003, 90: S8-15. 10.1016\/S0090-8258(03)00472-4.","journal-title":"Gynecol Oncol"},{"key":"551_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996, 334: 1-6. 10.1056\/NEJM199601043340101.","journal-title":"N Engl J Med"},{"key":"551_CR8","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003, 21: 3194-3200. 10.1200\/JCO.2003.02.153.","journal-title":"J Clin Oncol"},{"key":"551_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","volume":"4","author":"M Markman","year":"2003","unstructured":"Markman M: Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003, 4: 277-283. 10.1016\/S1470-2045(03)01074-X.","journal-title":"Lancet Oncol"},{"key":"551_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1055-3207(03)00030-9","volume":"12","author":"CR Rossi","year":"2003","unstructured":"Rossi CR, Mocellin S, Pilati P, Foletto M, Quintieri L, Palatini P, Lise M: Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am. 2003, 12: 781-794. 10.1016\/S1055-3207(03)00030-9.","journal-title":"Surg Oncol Clin N Am"},{"key":"551_CR11","first-page":"235","volume":"67","author":"ES Casper","year":"1983","unstructured":"Casper ES, Kelsen DP, Alcock NW, Lewis JL: Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep. 1983, 67: 235-238.","journal-title":"Cancer Treat Rep"},{"key":"551_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0090-8258(85)90118-0","volume":"20","author":"JA Lopez","year":"1985","unstructured":"Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF: Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol. 1985, 20: 1-9. 10.1016\/0090-8258(85)90118-0.","journal-title":"Gynecol Oncol"},{"key":"551_CR13","first-page":"1085","volume":"67","author":"RG Pretorius","year":"1983","unstructured":"Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, Lagasse LD: Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983, 67: 1085-1092.","journal-title":"Cancer Treat Rep"},{"key":"551_CR14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL, Rubin S, Curtin J, Barakat R, Phillips M: Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992, 10: 1485-1491.","journal-title":"J Clin Oncol"},{"key":"551_CR15","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","volume":"13","author":"P Francis","year":"1995","unstructured":"Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol. 1995, 13: 2961-2967.","journal-title":"J Clin Oncol"},{"key":"551_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF00273393","volume":"18","author":"MW DeGregorio","year":"1986","unstructured":"DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI: Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol. 1986, 18: 235-238. 10.1007\/BF00273393.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 2","key":"551_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1525-1438.2003.13360.x","volume":"13","author":"MJ Piccart","year":"2003","unstructured":"Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, Giurgea L, Coens C, Awada A, Vermorken JB: Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 5 a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003, 13 (Suppl 2): 196-203. 10.1111\/j.1525-1438.2003.13360.x.","journal-title":"Int J Gynecol Cancer"},{"key":"551_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1006\/gyno.1993.1038","volume":"48","author":"RA Segna","year":"1993","unstructured":"Segna RA, Dottino PR, Jennings TS, Cohen CJ: Feasibility of intraoperative administration of chemotherapy for gynecologic malignancies: assessment of acute postoperative morbidity. Gynecol Oncol. 1993, 48: 227-231. 10.1006\/gyno.1993.1038.","journal-title":"Gynecol Oncol"},{"key":"551_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1245\/ASO.2004.09.007","volume":"11","author":"SA Ahmad","year":"2004","unstructured":"Ahmad SA, Kim J, Sussman JJ, Soldano DA, Pennington LJ, James LE, Lowy AM: Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol. 2004, 11: 387-392. 10.1245\/ASO.2004.09.007.","journal-title":"Ann Surg Oncol"},{"key":"551_CR20","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/01.cad.0000176505.94175.d4","volume":"16","author":"B Royer","year":"2005","unstructured":"Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chauffert B, Heyd B, Kantelip JP, Pivot X: Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs. 2005, 16: 1009-1016. 10.1097\/01.cad.0000176505.94175.d4.","journal-title":"Anticancer Drugs"},{"key":"551_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00280-007-0484-x","volume":"61","author":"B Royer","year":"2008","unstructured":"Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, Kantelip JP, Chauffert B, Heyd B, Pivot X: Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother Pharmacol. 2008, 61: 415-421. 10.1007\/s00280-007-0484-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"551_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<779::AID-IJC19>3.0.CO;2-I","volume":"81","author":"C Duvillard","year":"1999","unstructured":"Duvillard C, Benoit L, Moretto P, Beltramo JL, Brunet-Lecomte P, Correia M, Sergent C, Chauffert B: Epinephrine enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors. Int J Cancer. 1999, 81: 779-784. 10.1002\/(SICI)1097-0215(19990531)81:5<779::AID-IJC19>3.0.CO;2-I.","journal-title":"Int J Cancer"},{"key":"551_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.2307\/2281868.","journal-title":"J Am Stat Assoc"},{"key":"551_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1200\/JCO.2005.05.2456","volume":"24","author":"M Markman","year":"2006","unstructured":"Markman M, Walker JL: Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006, 24: 988-994. 10.1200\/JCO.2005.05.2456.","journal-title":"J Clin Oncol"},{"key":"551_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","volume":"100","author":"JL Walker","year":"2006","unstructured":"Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006, 100: 27-32. 10.1016\/j.ygyno.2005.11.013.","journal-title":"Gynecol Oncol"},{"key":"551_CR26","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996, 335: 1950-1955. 10.1056\/NEJM199612263352603.","journal-title":"N Engl J Med"},{"key":"551_CR27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001, 19: 1001-1007.","journal-title":"J Clin Oncol"},{"key":"551_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006, 354: 34-43. 10.1056\/NEJMoa052985.","journal-title":"N Engl J Med"},{"key":"551_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/00006254-198709000-00001","volume":"42","author":"M Markman","year":"1987","unstructured":"Markman M: Intraperitoneal chemotherapy as treatment of ovarian carcinoma: why, how, and when?. Obstet Gynecol Surv. 1987, 42: 533-539. 10.1097\/00006254-198709000-00001.","journal-title":"Obstet Gynecol Surv"},{"key":"551_CR30","first-page":"43","volume":"12","author":"WW ten Bokkel Huinink","year":"1985","unstructured":"ten Bokkel Huinink WW, Dubbelman R, Aartsen E, Franklin H, McVie JG: Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol. 1985, 12: 43-46.","journal-title":"Semin Oncol"},{"key":"551_CR31","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978, 62: 1-11.","journal-title":"Cancer Treat Rep"},{"key":"551_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1048-891x.2004.14008.x","volume":"14","author":"M Look","year":"2004","unstructured":"Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004, 14: 35-41. 10.1111\/j.1048-891x.2004.14008.x.","journal-title":"Int J Gynecol Cancer"},{"key":"551_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ygyno.2003.10.002","volume":"92","author":"E Topuz","year":"2004","unstructured":"Topuz E, Eralp Y, Saglam S, Saip P, Aydiner A, Berkman S, Yavuz E: Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol. 2004, 92: 147-151. 10.1016\/j.ygyno.2003.10.002.","journal-title":"Gynecol Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-7-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T09:43:42Z","timestamp":1630489422000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-7-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-7-14","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,9]]},"assertion":[{"value":"21 June 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}